Jean Jacques Body

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi Bisphosphonate safety and tolerability
    Jean-Jacques Body
    Oncologist 10:317; author reply 318-9. 2005
  2. ncbi Bisphosphonates in metastatic bone disease: renal safety matters
    Jean-Jacques Body
    Institut Jules Bordet, , , 1000 Brussels, Belgium
    Oncologist 10:1-2. 2005
  3. ncbi Preclinical perspectives on bisphosphonate renal safety
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, 1 rue Héger Bordet, 1000 Brussels, Belgium
    Oncologist 10:3-7. 2005
  4. ncbi Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions
    Jean Jacques Body
    Supportive Care Clinic and Clinic of Endocrinology and Bone Diseases, Institut J Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast 12:S37-44. 2003
  5. ncbi Emergencies of calcium homeostasis
    Jean-Jacques Body
    Department of Medicine, Institut J Bordet, , Brussels, Belgium
    Rev Endocr Metab Disord 4:167-75. 2003
  6. ncbi International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients
    Jean Jacques Body
    Universite Libre de Bruxelles, Institut Jules Bordet and CHU Brugmann, Brussels, Belgium
    Eur J Cancer 43:852-8. 2007
  7. ncbi Profiling the safety and tolerability of bisphosphonates
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Semin Oncol 31:73-8. 2004
  8. ncbi Hypercalcemia of malignancy
    Jean Jacques Body
    Supportive Care Clinic and Clinic of Endocrinlogy and Bone Disease, Universite Libre de Bruxelles, Belgium
    Semin Nephrol 24:48-54. 2004
  9. ncbi [How to treat tumor-induced hypercalcemia]
    Jean Jacques Body
    Clinique des soins supportifs et clinique d endocrinologie maladies osseuses, Service de Medecine Interne, Institut Jules Bordet, Universite Libre de Bruxelles, B 1000 Bruxelles
    Rev Prat 53:2128-35. 2003
  10. ncbi Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
    J J Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Br J Cancer 90:1133-7. 2004

Detail Information

Publications62

  1. ncbi Bisphosphonate safety and tolerability
    Jean-Jacques Body
    Oncologist 10:317; author reply 318-9. 2005
  2. ncbi Bisphosphonates in metastatic bone disease: renal safety matters
    Jean-Jacques Body
    Institut Jules Bordet, , , 1000 Brussels, Belgium
    Oncologist 10:1-2. 2005
  3. ncbi Preclinical perspectives on bisphosphonate renal safety
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, 1 rue Héger Bordet, 1000 Brussels, Belgium
    Oncologist 10:3-7. 2005
    ..Further preclinical analyses are needed to confirm and evaluate differences among bisphosphonates...
  4. ncbi Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions
    Jean Jacques Body
    Supportive Care Clinic and Clinic of Endocrinology and Bone Diseases, Institut J Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast 12:S37-44. 2003
    ....
  5. ncbi Emergencies of calcium homeostasis
    Jean-Jacques Body
    Department of Medicine, Institut J Bordet, , Brussels, Belgium
    Rev Endocr Metab Disord 4:167-75. 2003
  6. ncbi International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients
    Jean Jacques Body
    Universite Libre de Bruxelles, Institut Jules Bordet and CHU Brugmann, Brussels, Belgium
    Eur J Cancer 43:852-8. 2007
    ..Physicians should choose the most appropriate bisphosphonate. Safety precautions are particularly important in elderly patients. Further research is needed in this population...
  7. ncbi Profiling the safety and tolerability of bisphosphonates
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Semin Oncol 31:73-8. 2004
    ..Using ibandronate could improve patient acceptability and simplify management, with reductions in the need for safety monitoring and management of adverse events...
  8. ncbi Hypercalcemia of malignancy
    Jean Jacques Body
    Supportive Care Clinic and Clinic of Endocrinlogy and Bone Disease, Universite Libre de Bruxelles, Belgium
    Semin Nephrol 24:48-54. 2004
    ..The use of bisphosphonates in placebo-controlled trials has shown that the incidence of hypercalcemic episodes is reduced by more than one half...
  9. ncbi [How to treat tumor-induced hypercalcemia]
    Jean Jacques Body
    Clinique des soins supportifs et clinique d endocrinologie maladies osseuses, Service de Medecine Interne, Institut Jules Bordet, Universite Libre de Bruxelles, B 1000 Bruxelles
    Rev Prat 53:2128-35. 2003
    ..They reduce the incidence of all complications of metastatic bone disease, including cancer hypercalcemia...
  10. ncbi Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
    J J Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Br J Cancer 90:1133-7. 2004
    ..Oral ibandronate 50 mg is an effective, well-tolerated and convenient treatment for the prevention of skeletal complications of metastatic bone disease...
  11. ncbi Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results
    J J Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Cancer Care (Engl) 15:299-302. 2006
    ..v. ibandronate 6 mg infused every 3-4 weeks for 2 years. Comparative trials to examine the renal safety of ibandronate and other i.v. bisphosphonates are warranted...
  12. ncbi Tumor bone disease
    J-J Body
    Dept of Internal Medicine, Inst. J. Bordet, , , B-1000 Brussels, Belgium
    Ann Endocrinol (Paris) 67:166-72. 2006
  13. ncbi A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Jean Jacques Body
    Department of Medicine, Institut Jules Bordet, Brussels, Belgium
    Clin Cancer Res 12:1221-8. 2006
    ..Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, was developed to treat patients with skeletal diseases...
  14. ncbi Treatment of tumor-induced hypercalcemia: a solved problem?
    Jean Jacques Body
    Supportive Care Clinic, Institut J Bordet, Universite Libre de Bruxelles, Belgium
    Expert Rev Anticancer Ther 3:241-6. 2003
    ..Recurrent hypercalcemia is nevertheless difficult to control and antibodies against parathyroid-hormone-related protein may prove to be a useful treatment...
  15. ncbi Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis
    Jean Jacques Body
    Supportive Care Clinic, Clinic of Endocrinology and Bone Diseases and Laboratory of Endocrinology and Breast Cancer Research, Dept of Medicine, Institut J Bordet, 1 rue Héger Bordet, Univ Libre de Bruxelles, Brussels, Belgium
    Expert Opin Pharmacother 4:567-80. 2003
    ..Zoledronic acid has the potential to change the treatment of osteoporosis dramatically...
  16. ncbi Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis
    J J Body
    Supportive Care Clinic and Endocrinology Bone Diseases Clinic, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Bone 30:75S-79S. 2002
    ....
  17. ncbi Bisphosphonates in the treatment of metastatic breast cancer
    J J Body
    Department of Medicine, Institut Jules Bordet, Univ Libre de Bruxelles, Belgium
    J Mammary Gland Biol Neoplasia 6:477-85. 2001
    ....
  18. ncbi Bisphosphonates for cancer patients: why, how, and when?
    J J Body
    Department of Medicine, Institut J Bordet, 1, Rue Heger Bordet, 1000 Bruxelles, Belgium
    Support Care Cancer 10:399-407. 2002
    ..For that matter, initial data with clodronate indicate that they have the potential to prevent the development of bone metastases, but the use of BPs in the adjuvant setting must still be viewed as experimental...
  19. ncbi A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    Jean Jacques Body
    Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    J Clin Endocrinol Metab 87:4528-35. 2002
    ..In conclusion, teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate...
  20. ncbi Management of primary osteoporosis
    J J Body
    Clinic of Endocrinology and Bone Diseases, and Supportive Care Clinic, Dept of Medicine, Institut J Bordet, 1, rue Héger Bordet Univ Libre de Bruxelles, Brussels Belgium
    Acta Clin Belg 57:277-83. 2002
    ..On the other hand, bone-forming agents, such as daily subcutaneous injections of teriparatide (rhPTH 1-34) offer exciting perspectives for the treatment of severe osteoporosis despite the complexity of such therapy...
  21. ncbi Effectiveness and cost of bisphosphonate therapy in tumor bone disease
    Jean Jacques Body
    Supportive Care Clinic and Clinic of Endocrinology Bone Diseases, Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer 97:859-65. 2003
    ..Osteoclast-mediated bone resorption is reported to be increased markedly in patients with tumor bone disease and can be inhibited by bisphosphonate therapy...
  22. ncbi Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
    J J Body
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 18:1165-71. 2007
    ..Phase III study comparing the effect of oral ibandronate and intravenous zoledronic acid on bone markers...
  23. ncbi Bisphosphonates for malignancy-related bone disease: current status, future developments
    Jean Jacques Body
    Department of Internal Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Belgium
    Support Care Cancer 14:408-18. 2006
    ..Such interesting new developments may underpin a new era of bisphosphonate use sometime in the near future...
  24. ncbi Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts
    Hichame Id Boufker
    Laboratoire d Hematologie Experimentale, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Bone 49:1219-31. 2011
    ....
  25. ncbi Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines
    Fabrice Journe
    Laboratory of Endocrinology and Bone Diseases and Department of Internal Medicine, Institut J Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res 8:R2. 2006
    ..These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-positive (ER+) breast cancer cells...
  26. ncbi Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines
    Fabrice Journe
    Department of Internal Medicine, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, 1 rue Héger Bordet, 1000, Brussels, Belgium
    Clin Exp Metastasis 23:135-47. 2006
    ..Our data might provide a rationale for associating bisphosphonates and radiotherapy for the treatment of bone metastases from breast cancer...
  27. ncbi Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation
    Fabrice Journe
    Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res Treat 107:49-61. 2008
    ..The occurrence of such a crosstalk calls for some caution regarding the pharmacological use of FXR agonists...
  28. ncbi Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma
    Fabrice Journe
    Laboratory of Endocrinology Bone Diseases, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res Treat 86:39-53. 2004
    ..PgR induction due to E(2) was not modified by MG-132. Interestingly, MG-132 alone produced an ER-independent increase of PgR expression. IBEP-2 might prove to be valuable to study ER-mediated induction of PgR...
  29. ncbi Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells
    Fabrice Journe
    Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Universite Libre de Bruxelles, Rue Heger Bordet, B 1000, Brussels, Belgium
    Breast Cancer Res 10:R4. 2008
    ..Although their therapeutic effects mainly result from an inhibition of osteoclastic bone resorption, in vitro data indicate that they also act directly on breast cancer cells, inhibiting proliferation and inducing apoptosis...
  30. ncbi Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer
    Jean Jacques Body
    Institut Jules Bordet, Universite Libre de Bruxelles, 1 rue Héger Bordet, 1000 Brussels, Belgium
    Pain 111:306-12. 2004
    ..Oral ibandronate had beneficial effects on bone pain and quality of life and was well tolerated. These results suggest that this treatment is of considerable clinical value as a co-analgesic to patients with painful bone metastases...
  31. ncbi Denosumab for the management of bone disease in patients with solid tumors
    Jean Jacques Body
    Centre Hospitalier Universitaire Brugmann, Universite Libre de Bruxelles, 4 Place Van Gehuchten, 1020 Brussels, Belgium
    Expert Rev Anticancer Ther 12:307-22. 2012
    ..This article examines the pharmacokinetics, efficacy, and safety and tolerability of denosumab for the management of bone events in patients with cancer...
  32. ncbi Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells
    Jean Claude Dumon
    Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Eur Urol 45:521-8; discussion 528-9. 2004
    ..Bisphosphonates are potent inhibitors of bone resorption frequently used for breast cancer and myeloma-induced bone disease. Zoledronic acid has been recently shown to also reduce skeletal morbidity from prostate cancer...
  33. ncbi Response to alendronate in osteoporotic women previously treated with pamidronate
    Anne Peretz
    The Internal Medicine Department, CHU Brugmann, 4 Place Van Gehuchten, B 1020, Brussels, Belgium
    Maturitas 44:111-5. 2003
    ..It is unclear how shifting from a treatment with one bisphosphonate to another will influence the evolution of BMD and bone turnover...
  34. ncbi Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
    Jean Jacques Body
    CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    J Bone Miner Res 25:440-6. 2010
    ..Denosumab appeared to be well tolerated in both studies. Denosumab suppresses bone resorption markers independently of prior BP treatment, even in patients who appear to respond poorly to BPs...
  35. ncbi New developments for treatment and prevention of bone metastases
    Jean Jacques Body
    Department of Medicine, CHU Brugmann, Universite Libre De Bruxelles U L B, Brussels, Belgium
    Curr Opin Oncol 23:338-42. 2011
    ..To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors...
  36. ncbi Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy
    Isolde Ramon
    Department of Internal Medicine Endocrinology, University Hospital Brugmann, Free University of Brussels, Belgium
    Calcif Tissue Int 89:442-5. 2011
    ..Studies directed at the identification of the molecular pathways in bone mediating the interference of GCs with phosphate metabolism are warranted...
  37. ncbi The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
    Hichame Id Boufker
    Laboratoire d Hematologie Experimentale, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 10:298. 2010
    ..It has also shown promising results in preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never been examined...
  38. ncbi A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
    Jean-Jacques Body
    Unit of Endocrinology, Institut Jules Bordet, Brussels, Belgium
    Cancer 97:887-92. 2003
    ..Changes were comparable to those with pamidronate. AMGN-0007 was well tolerated...
  39. ncbi Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health
    Fabrice Journe
    Universite Libre de Bruxelles ULB, Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Expert Opin Drug Saf 7:241-58. 2008
    ..We conclude that, because of its therapeutic efficacy and its seemingly minimal effect on bone integrity, fulvestrant represents a new option for the hormonal treatment of breast cancer that deserves further clinical evaluation...
  40. ncbi Increased fracture rate in women with breast cancer: a review of the hidden risk
    Jean Jacques Body
    CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 11:384. 2011
    ..Our purpose is to review current evidence for BMD loss and fracture risk during treatment for breast cancer and discuss pharmacologic means to reduce this risk...
  41. ncbi Successful use of ketamine for intractable cancer pain
    Dominique A Lossignol
    Institut Jules Bordet, Clinique des Soins Supportifs et des Soins Palliatifs, Service de Medecine Interne, Universite Libre de Bruxelles, 1 rue Héger Bordet, 1000, Brussels, Belgium
    Support Care Cancer 13:188-93. 2005
    ..The emergence of intractable pain may notably be due to the activation of N-methyl-D-aspartate (NMDA) receptors located in the central nervous system. NMDA antagonists might thus be an interesting approach in such pain syndromes...
  42. ncbi Breast cancer: bisphosphonate therapy for metastatic bone disease
    Jean-Jacques Body
    Department of Internal Medicine, Institut Jules Bordet, , Brussels, Belgium
    Clin Cancer Res 12:6258s-6263s. 2006
    ..Osteonecrosis of the jaw could occur in up to 2.5% of breast cancer patients during long-term bisphosphonate therapy. It is often a significant complication that seems to be linked with the duration of therapy...
  43. ncbi Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study
    Isabelle Mancini
    Supportive Care Clinic, Department of Internal Medicine, Institut Jules Bordet, , Bruxelles, Belgium
    J Clin Oncol 22:3587-92. 2004
    ..CONCLUSION: Nonstandard, intensive treatment with i.v. ibandronate seems to have a marked analgesic effect in patients with opioid-resistant bone pain from metastatic bone disease. Further investigation is warranted...
  44. ncbi European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice survey
    Nicolas Magne
    Département de Radio Oncologie, Institut Jules Bordet, Bruxelles, Belgium
    Support Care Cancer 19:1565-72. 2011
    ..This study seeks to perform a survey of patterns of practice among the different physicians involved in the bone metastases management, with special focus on external beam radiotherapy (EBRT)...
  45. ncbi Psychosocial rehabilitation of cancer patients after curative therapy
    Alain Ronson
    Supportive Care Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    Support Care Cancer 10:281-91. 2002
    ....
  46. ncbi Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
    Jean-Pierre Devogelaer
    Rheumatology Unit, Saint-Luc University Hospital, , Brussels, Belgium
    Osteoporos Int 17:8-19. 2006
    ..There is indeed no proof that the increased costs of combined treatments will translate into increased therapeutic efficacy...
  47. ncbi Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients
    Fabrice Journe
    Laboratory of Endocrinology and Translational Research Unit, Department of Internal Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res Treat 115:523-35. 2009
    ..These results suggest that ER-positive breast tumors could be stimulated to proliferate via a crosstalk between FXR and ER, particularly in a state of estrogen deprivation (menopause, aromatase inhibitors)...
  48. ncbi Fibroblast growth factor 23 and its role in phosphate homeostasis
    Isolde Ramon
    Department of Internal Medicine Endocrinology, Brugmann University Hospital, Free University of Brussels, Brussels, Belgium
    Eur J Endocrinol 162:1-10. 2010
    ..This review describes current knowledge on fibroblast growth factor 23, which is one of the best studied phosphatonins...
  49. ncbi Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, 80227, USA
    J Rheumatol 32:1556-62. 2005
    ..To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study...
  50. ncbi Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
    Robert E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
    Cancer Treat Rev 34:S31-42. 2008
    ....
  51. ncbi Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
    Allan Lipton
    Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Clin Oncol 25:4431-7. 2007
    ..In this study, we evaluated the efficacy and safety of five dosing regimens of denosumab in patients with breast cancer-related bone metastases not previously treated with intravenous bisphosphonates (IV BPs)...
  52. ncbi Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways
    Denis Nonclercq
    Laboratory of Histology and Experimental Cytology, Faculty of Medicine and Pharmacy, Pentagone 1B, , 6 Avenue du Champ de Mars, B7000 Mons, Belgium
    Mol Cell Endocrinol 227:53-65. 2004
    ..Besides, the protective effect of partial antiestrogens suggests that ER stability is only compromized by Hsp90 disruption when the receptor is in its native, unliganded form...
  53. ncbi Ibandronate reduces skeletal morbidity in patients with breast cancer
    Debu Tripathy A
    University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Semin Oncol 31:64-6. 2004
    ..These results show that IV and oral ibandronate effectively reduce skeletal morbidity in breast cancer patients with bone metastases...
  54. ncbi Ibandronate in metastatic bone pain
    Axel Heidenreich
    Division of Oncological Urology, Department of Urology, University of Cologne, Germany
    Semin Oncol 31:67-72. 2004
    ..This clinical benefit may reduce the burden of metastatic bone disease on health care resources by limiting the need for analgesics and radiotherapy to the bone...
  55. ncbi Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 346:653-61. 2002
    ..Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored...
  56. ncbi Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial
    Martin Pecherstorfer
    Wilhelminenspital, Vienna, Austria
    Clin Drug Investig 26:315-22. 2006
    ..In this study, the safety of ibandronic acid was examined over a period of 4 years...
  57. ncbi PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor
    Gert G Van den Eynden
    Translational Cancer Research Group Antwerp Department of Pathology University of Antwerp University Hospital Antwerp, 2650 Edegem, Belgium
    Bone 40:1166-71. 2007
    ..Our findings furthermore suggest that the tumoral production of calcitonin and PTHrP might have contributed to the increased bone mineral storage of calcium and thus probably attenuated the development of frank hypercalcemia...
  58. ncbi Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments
    Paul Andreas Compare Cloos
    Nordic Bioscience, Herlev, Denmark
    Breast Cancer Res 5:R103-9. 2003
    ..The purpose of the present study was to test the ability of the various CTX forms to identify breast cancer patients with bone metastases and to investigate whether such patients had an altered CTX excretion pattern...
  59. ncbi Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials
    Debu Tripathy
    University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Clin Ther 26:1947-59. 2004
    ..Metastatic bone disease is a serious clinical problem in patients with advanced cancer. Bisphosphonates inhibit the activity of osteoclasts and are the treatment of choice for bone metastases...
  60. ncbi Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference
    Allan Lipton
    Milton S Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA, and Department of Oncology, Norwegian Radium Hospital, Oslo, Norway
    Clin Cancer Res 12:6209s-6212s. 2006
    ..The conclusions reached during the 2-day meeting are summarized in this article and presented in more detail in the individual articles and accompanying discussion sessions that comprise the conference proceedings...
  61. ncbi Ibandronate in metastatic bone disease: a review of preclinical data
    Frieder Bauss
    Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
    Anticancer Drugs 16:107-18. 2005
    ..Recent studies in rat models demonstrate improved osseointegration of joint implants following ibandronate therapy, with potential application in patients with conditions such as degenerative arthritis or osteoporosis...
  62. ncbi Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
    Steven Boonen
    Center for Metabolic Bone Diseases, Katholieke University Leuven, Leuven, Belgium
    Osteoporos Int 16:239-54. 2005